Vericel to Present at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) announced that President and CEO Nick Colangelo will present a company overview at the Oppenheimer 31st Annual Healthcare Conference. The virtual presentation is scheduled for March 17, 2021, at 10:00 a.m. Eastern Time. A live webcast will be available on the Investor Relations section of the Vericel website. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing cell therapy products MACI® and Epicel® in the U.S., and holds exclusive rights to NexoBrid® for severe thermal burn treatment.

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Oppenheimer 31^st Annual Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Wednesday, March 17, 2021, at 10:00 a.m. Eastern Time.

A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid^®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2021 Vericel Corporation. All rights reserved.

Investor Contacts:
Eric Burns
ir@vcel.com
+1 734-418-4411

FAQ

What is the date and time of the Vericel presentation at the Oppenheimer Healthcare Conference?

The Vericel presentation is scheduled for March 17, 2021, at 10:00 a.m. Eastern Time.

Where can I watch the Vericel Corporation presentation live?

The live webcast of the Vericel presentation will be available on the Investor Relations section of their website.

Who is presenting at the Oppenheimer Conference for Vericel Corporation?

Nick Colangelo, President and CEO, will present at the Oppenheimer 31st Annual Healthcare Conference.

What products does Vericel Corporation market?

Vericel markets MACI® and Epicel® for sports medicine and severe burn care.

What is NexoBrid® and its significance to Vericel Corporation?

NexoBrid® is a registration-stage biological orphan product licensed to Vericel for the debridement of severe thermal burns.